Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ventana Files Law Suit Against Watlow
As per the complaint, Ventana purchased more than $1 million in heater cap assemblies from Watlow on June 30, 2007. Ventana says it provided its specifications for the
As per the complaint, Ventana purchased more than $1 million in heater cap assemblies from Watlow on June 30, 2007. Ventana says it provided its specifications for the
Mr Aselage is currently senior vice president of global commercial development at BioMarin Pharmaceuticals. Prior to joining BioMarin, he held the position of executive vice president of global
The new collaboration will focus on late-stage development and commercialization of a new generation of human stem cell-based biological tools enabling Clinical Trials in a Test Tube and
Mr Mittelstadt began research in surgical robotics in 1986 as a visiting research scientist at the IBM TJ Watson Research Center and is responsible for much of the
This will be in combination with substantial investment on clinical research for generating India-specific data for both, new product development, and marketing existing products. The company plans to
The non-exclusive agreement provides Funakoshi with the rights to distribute in Japan. Among the Standardized RT-PCR reagents (StaRT-PCR) based research molecular tools are kits for chronic myelogenous leukemia,
Lyfetec and its management develop personal medical screening technology. Technologies and assets included in the contemplated acquisition include in-home test kits for the diagnosis and early detection of
These three trials will provide additional data on mipomersen in high-risk patient populations. The new studies, together with ongoing trials, will also substantially increase the size of the
The FDA considers the recommendations of its advisory committees when making its determinations. If approved, ATryn will be the first recombinant human antithrombin available in the US, said
This Phase IIb trial is a randomized, open-label, multi-center, active-controlled, adaptive-design dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every four weeks plus daily